Thirteen-year nationwide trends in use of XXXX and subsequent long-term survival.

@entity1 @entity1479 @entity8 @entity712 @entity6 @entity409 @entity737
BACKGROUND: Long-term trends in use of @entity737 ( @entity737 ) and outcomes are rare. OBJECTIVE: We examined 13-year nationwide trends in @entity1479 implantation and survival rates in Denmark. METHODS: Using medical databases, we identified all first time @entity1479 recipients in Denmark during 2000-2012 (N = 8460) and ascertained all-cause mortality. We computed standardized annual implantation rates and mortality rate ratios according to age, sex, comorbidity level, indication, and device type. RESULTS: The standardized annual implantation rate increased from 42 per million @entity1 in 2000 to 213 per million @entity1 in 2012 (from 34 to 174 for @entity1 and from 8 to 39 for @entity1 ). The increase was driven by secondary prophylactic @entity737 until 2006 and primary prophylactic @entity737 thereafter. The increase occurred particularly in older @entity1 and those with a high level of comorbidity. Independent of indication, 76% of all @entity1 with @entity1479 were alive after 5 years. @entity1 had a higher mortality rate compared with @entity1 (mortality rate ratio 1.28; 95% confidence interval 1.10-1.49). Compared with low comorbidity level, moderate, severe, and very severe comorbidity levels were associated with 1.6-, 2.5-, and 4.9-fold increased mortality rates, respectively. The most influential individual comorbidities were @entity712 , @entity6 , @entity409 , and @entity8 . CONCLUSION: The annual implantation rate of @entity737 increased 5-fold in Denmark between 2000 and 2012. The rate increase occurred for both @entity1 and @entity1 , but particularly in the elderly and @entity1 with severe comorbidity. Five-year survival probability was high, but severe comorbidity and male sex were associated with shorter survival.
